Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
A Prospective Population Pharmacokinetic Analysis of Sapropterin Dihydrochloride in Infants and Young Children with Phenylketonuria.
[phenylketonuria]
Untreated
phenylketonuria
(
PKU
)
,
a
hereditary
metabolic
disorder
caused
by
a
genetic
mutation
in
phenylalanine
hydroxylase
(
PAH
)
,
is
characterized
by
elevated
blood
phenylalanine
(
Phe
)
and
severe
neurologic
disease
.
Sapropterin
dihydrochloride
,
a
synthetic
preparation
of
naturally
occurring
PAH
cofactor
tetrahydrobiopterin
(
BH
4
)
,
activates
residual
PAH
in
a
subset
of
patients
,
resulting
in
decreased
blood
Phe
and
increased
Phe
tolerance
.
The
objective
of
this
study
was
to
determine
the
appropriate
dose
of
sapropterin
in
pediatric
patients
(
0
-
6
Â
years
)
.
The
study
design
used
D-
optimization
and
was
prospectively
powered
to
achieve
precise
estimates
of
clearance
and
volume
of
distribution
.
Oral
sapropterin
(
5
or
20
Â
mg
/
kg
)
was
administered
once
daily
.
Sapropterin
plasma
concentrations
were
measured
by
a
validated
method
.
Population
pharmacokinetic
analysis
was
performed
with
NONMEM
(
®
)
version
7
.
2
on
pooled
data
from
156
pediatric
and
adult
PKU
patients
in
two
phase
III
clinical
studies
.
The
best
pharmacokinetic
model
was
a
one
-compartment
model
with
an
absorption
lag
,
first
-order
input
,
and
linear
elimination
,
with
a
factor
describing
endogenous
BH
4
levels
.
Body
weight
was
the
only
covariate
significantly
affecting
sapropterin
pharmacokinetics
.
Based
on
recommended
dosing
,
exposure
across
age
groups
was
comparable
.
The
absorption
rate
and
terminal
half
-life
suggest
flip
-flop
pharmacokinetic
behavior
where
absorption
is
rate
limiting
.
The
effect
of
weight
on
sapropterin
pharmacokinetics
was
significant
and
exposure
was
comparable
across
age
groups
;
thus
,
weight-based
dosing
is
appropriate
.
The
doses
selected
for
pediatric
patients
provided
similar
exposure
as
in
adults
.
Given
the
slow
absorption
and
elimination
half
-life
,
once-daily
dosing
is
justified
.
Diseases
Validation
Diseases presenting
"blood phenylalanine"
symptom
classical phenylketonuria
phenylketonuria
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom